Castillo GLA

Language: Spanish
References: 41
Page: 3-13
PDF size: 512.75 Kb.

ABSTRACT

Mucormycosis embraces an infection group caused by a fungus of the Rhizomucor genus, which is pathogenic under conditions of immunodeficiency, such as in diabetes and AIDS. There are several forms of clinical presentations, including rhinocerebral, pulmonary, mucocutaneous, gastrointestinal and disseminated ones. The rhinocerebral type is rare and very agressive, with morbimortality rates of 85-100% at one year despite the use of multiroute amphotericin B and hyperbaric therapy.

REFERENCES

1. l. Collins DM, Dillard TA. Grathwohl KW et al. Bronchial mucormycosis with progressive air trapping. Mayo Clinic Proceedings 1999; 74(7): 698-701.

2. Gregory JE, Golden A, Haymaker E. Mucormycosis of the central nervous system: report of three cases. Bull Johns Hopkins 1943; 73: 405-19.

3. Plaignaud M. Observation sur fungus de sinus maxillaire. J Chir 1791; 1: 111-16.

4. Arenas R. Micología médica. 1a. Ed. Ed. Interamericana; 1993, p. 241-53.

5. Platauf A. Mycosis mucorina. Virchow Arch 1885; 102: 543-64.

6. Baker RD. Mucormycosis: a new disease? JAMA 1957; 163: 805-8.

7. Harris JS. Mucormycosis: a report of a case. Pediatrics 1955; 16: 857-67.

8. Chick EW, Evans J, Baker RD. The inhibitory effect of amphotericin B on localized Rhizopus oryzae infection utilizing pneumoderma pouch of rat. Antibiot Chemother 1958; 8: 506-10.

9. Chick EW, Evans J, Baker RD. Treatment of mucormycosis in rabbits with amphotericin B. Antibiot Chemother 1958; 8: 394-7.

10. Glazer, Mendel, Nusair et al. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 1999 ; 117: 279-82.

11. Wall SJ, Lee KH, Alvarez JD. Quiz case 1. Archives of Otorryn- Head and Neck Surgery. 126: 236-239

12. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: Evolution of the disease and treatment option. Laryngoscope 1997; 107: 855-62.

13. Rubin SA, Chaljub G, Winer-Muram HT, Flicker S. Pulmonary zymomucosis: a radiographic and clinical spectrum. J Thorac Imaging 192; 7: 85-90.

14. Adam RD. Hunter G. Mucormycosis: Emerging prominence of cutaneous infections. Clinc Infect Disease 1994; 125: 67-70.

15. Kellei MA, Wu Chin L. Weekly clinicophatological exercises: cases 22. 1999: a 68 year old woman with multiple myeloma, diabetes mellitus and an inflamed eye. New Eng J Med 1999; 241: 265-73.

16. deShazo, Richard D, O’Brien M, Chapin K, et al. A new classification and diagnostic criteria for invasive fungal sinusitis. Archives of Otolaringology-Head Neck Surgery; 123: 1181-8.

17. Heinz TP, Schell W. Soft-tissue fungal infections: Surgical management of 12 inmunocompromised patients. Plast Reconstr Surg 1996; 97: 1391.

18. Alder DE, Milhorat TH, John I. Treatment of rhinocerebral mucormycosis with intravenous, interstitial, and cerebrospinal fluid administration of amphotericin B: case report. Neurosurgery 1998; 42: 644-9.

19. Greenberg MR, Lippman SM, Grinnel VS, Colman MF. Computed tomographic findings in orbital mucor. West J Med 1985; 143: 102-3.

20. Anand VK, Alemar G, Griswold JA. Intracranial complications of mucormycosis: An experimental model and clinical review. Laryngoscope 1992; 102: 656-62.

21. Pagano L, Ricci P, Tonso A, Nasari A, et al. Mucormycosis in patient with heamatological malignancies: a retrospective clinical study of 37 cases. B J Haematol 1997; 99: 331-6.

22. Sanchez MR, Ponge WI. Zygomycosis ands HIV infection. J Am Acad Dermatol 1999; 30: 904-8.

23. Armstrong D. Treatment of opportunistic fungal infection. Clinic Infect Dis 1992; 16: 1-9.

24. Smith CM. Farmacología. 1a. Ed. Editorial Panamericana; 1996, p. 839-40.

25. Cuadrado LM, Guerrero A, Asenjo JLG, Martín F. Cerebral mucormycosis in two cases of acquired immunodeficiency syndrome. Arch Neurol 1998; 45: 109-11.

26. Masucci EF, Fabara JA, Saini N, Kurtzke JF. Cerebral mucormycosis in a heroin addict. Arch Neurol 1982; 39: 304-6.

27. Murphy RA, Miller WT Jr. Pulmonary mucormycosis. Semin Roentgenol 1996; 31: 83-7.

28. McAdams HP, Rosado de Christenson M, Strollo DC. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997; 168: 1541-8.

29. Kucers A, Bennett N, Kemp RJ. The use of antibiotics: A comprehensive review with clinical emphasis. Philadelphia, J.B. Lippincott; 1987, p. 1449-50.

30. Robert HJ, Chesterman AT. Ampotericina B vía intravenosa. Indicaciones dús i criteris d´utilitzacióen les infeccions fúngiques sistemiques. Butlleti del medicament 1999; 1: 1231-6.

31. Cohen J. Antifungal chemotherapy. Lancet 1982; 2: 532-5.

32. Bell WE. Treatment of fungal infection of the central nervous system. Ann Neurol 1981; 9: 417-22.

33. Martindale CA. The complete drug reference XXXII. Londres: The Pharmaceutical Press; 1999, p. 372-5.

34. Schoffski P. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumoniaes or fever of unknown origin: randomized study. Brist J Med, 1998; 317: 379-84.

35. Walsh TJ. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl Med 1999; 340: 764-71.

36. Tollemar J, Rengden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drugs Safety 1995; 13: 207-18.

37. Leenders AC. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570-5.

38. Hamill R, Oney LA, Cranel LR. Successful therapy for rhinocerebral mucormycosis with associated bilateral brain abscesses. Arch Intern Med 1983; 141: 581-3.

39. Langmayr JJ, Schwarz A, Buchberger W, Hochleitner W. Local amphotericin for fungal brain abscess. Lancet 1993; 342: 123-7.

40. Jeffrey DM, Beeard ME, Ikram RB. Intranasal amphotericin B reduce the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-92.

41. Bentur, Yedidia Shupak. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Recons Surg 1998; 102: